Thu, Oct 23, 2014, 6:12 AM EDT - U.S. Markets open in 3 hrs 18 mins


% | $
Quotes you view appear here for quick access.

Tetraphase Pharmaceuticals, Inc. Message Board

  • popeyethesailor61 popeyethesailor61 Aug 14, 2013 10:37 PM Flag

    new article

    In July, Tetraphase was granted the Qualified Infectious Disease Product (QIDP) designation for eravacycline (TP-434) in cIAIs and cUTIs. This designation enables priority review and eligibility for fast-track status, as well as the potential for a five-year extension of patent exclusivity.

    The antibiotic is in Phase III trials for cUTIs. This synthetic, intravenously administered tetracycline is a broad-spectrum antibiotic for multi-drug-resistant infections. Additional compounds are in preclinical development. The company also is working to create oral antibiotics.

23.41-0.48(-2.01%)Oct 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.